FY2025 · ended Dec 31, 2025 · Revenue $112.82M, -5.9% YoY · Filed Mar 3, 2026
Anika Therapeutics, Inc. (ANIK) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $112.8 million and a net loss of $10.9 million. Free cash flow was $4.4 million. As of Jun 30, 2026 it held $38.4 million in cash and investments and $25.2 million in total debt.
Revenue (TTM)
$120.65M
+5.3% vs year-ago TTM
Net income (TTM)
$-3.78M
+93.8% vs year-ago TTM
Operating cash flow (TTM)
$5.98M
-4.8% vs year-ago TTM
Free cash flow (TTM)
$562,000
+205.0% vs year-ago TTM
EPS (TTM)
$-0.27
+93.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
13.40M
-5.5% vs prior year
Net cash
$13.16M
as of Jun 30, 2026
Operating margin
-4.2%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- ANIK (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bedford, MA
- SEC filer status
- Accelerated filer
- SEC CIK
- 898437
- Former names
- ANIKA THERAPEUTICS INC (until Mar 13, 2014); ANIKA RESEARCH INC (until Nov 27, 1996)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $112.8M | $119.9M | $120.8M | $113.8M | $147.8M |
| Operating income | -$11.1M | -$5.1M | $844,000 | $3.7M | $2.6M |
| Net income | -$10.9M | -$56.4M | -$82.7M | -$14.9M | $4.1M |
| Diluted EPS | -$0.76 | -$3.83 | -$5.64 | -$1.02 | $0.28 |
| Operating cash flow | $11.2M | $5.4M | -$1.8M | $4.4M | $8.4M |
| Free cash flow | $4.4M | -$2.3M | -$7.2M | -$3.1M | $3.3M |
| Total assets | $190.3M | $202.7M | $270.6M | $349.1M | $347.5M |
| Stockholders' equity | $143.5M | $154.0M | $212.3M | $285.6M | $287.1M |
| Cash and investments | $81.2M | $79.2M | $95.1M | $121.0M | $124.2M |
| Total debt | $26.2M | $25.9M | $25.9M | $28.8M | $19.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 14, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 23, 2026 | Jun 18, 2026 |
| 10-Q | Quarterly report | Apr 30, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Apr 29, 2026 | Apr 24, 2026 |
All 1004 Anika Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.